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Background: Silencing of P16 through methylation and locus deletion is the most frequent early events in
carcinogenesis. The aim of this study is to prospectively determine if early P16 methylation is a predictor for
oral cancer development.
Methods: Patients (n= 181) with mild or moderate oral epithelial dysplasia (OED) were recruited into the dou-
ble blindmulticentre cohort. P16methylationwas analyzed using theMethyLight assay. Progression of OEDswas
monitored for a minimum 3 year follow-up period.
Findings: P16 methylation-informative cases (n = 152) were enrolled in the prospective multicenter cohorts
with an ultimate compliance of 96.7%. OED-derived squamous cell carcinomas were observed in 21 patients
(14.3%) during the follow-up (median, 41.0 months). The cancer progression rate from the P16 methylation-
positive patients was signiﬁcantly increased when compared to P16 methylation-negative patients [27.1% vs
8.1%; adjusted odds ratio = 4.6; P = 0.006]. When the P16 methylation-positive criteria were used as a
biomarker for early prediction of cancer development from OEDs, sensitivity and speciﬁcity of 62% and 76%
were obtained, respectively.
Interpretation: P16methylation is unequivocally a marker for determining the malignant potential of OED and
there is no need for further research regarding this aspect.
Funding: National Basic Research Programs of China (2011CB504201 and 2015CB553902), Beijing Science and
Technology Commission (Z090507017709016), and Beijing Municipal Administration of Hospital (XM201303)
to Dajun Deng. The funding agencies have no role in the actual experimental design, patient recruitment, data col-
lection, analysis, interpretation, or writing of this manuscript.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
P16 (CDKN2A) is the most frequently deleted locus in cancer
genomes and has been studied extensively (Beroukhim et al., 2010;
Liu et al., 1995; Hussussian et al., 1994; Kannengiesser et al., 2009).
While genetic alterations in P16 do occur, gene methylation is far
more prevalent in human cancers such as oral squamous cell carcinoma
(OSCC) (Merlo et al., 1995; Serrano et al., 2000; Herman et al., 1995;pital Medical University Beijing
cinogenesis and Translational
logy, Peking University Cancer
, dengdajun@bjmu.edu.cn
. This is an open access article underGonzalez-Zulueta et al., 1995; Kresty et al., 2002). Studies have also
shown that increased P16methylation correlates with decreased levels
of expression and has been linked to the development and prognosis in
many cancers (Sun et al., 2004; Belinsky et al., 2006; Luo et al., 2006;
Hall et al., 2008; Cao et al., 2009). P16methylationmay also play impor-
tant roles in carcinogenesis (Yu et al., 2014).
Oral leukoplakia is the most common precancerous condition
(Kramer et al., 1978). Studies have shown that 17–25% of oral leukopla-
kia lesions contain oral epithelial dysplasia (OED), and about 8% will
progress to OSCC (Bouquot and Gorlin, 1986; Bouquot and Whitaker,
1994). The P16 inactivation rate in end-stage head and neck carcinomas
has been reported to be as high as 70–85% (Cairns et al., 1995; Reed
et al., 1996; Riese et al., 1999; Danahey et al., 1999). One study found
that the P16 methylation rate (58%) was much higher than the P16
mutation rate (15%) in 28 severe OED lesions (Kresty et al., 2002). P16
methylation is also frequently detected in mild/moderate OED lesionsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Hall et al., 2008; Cao et al., 2009). However, the feasibility of using
P16 methylation to predict malignant progression of OED has not yet
been validated in a multicenter study. Therefore, such a study among
Chinese patients with OED was carried out using P16methylation as a
clinical classiﬁer. This study provides evidence strongly supporting
that P16 methylation could be used as a biomarker for predicting the
malignant transformation of OED early in the course of the disease.
2. Methods
2.1. Study Design
181 patients withmild ormoderate OEDwere selected from cases of
oral leukoplakia, lichen planus, or chronic discoid erythematosus at
Peking University School of Stomatology (Central-A, n = 82), Capital
Medical University School of Stomatology (Central-B, n = 68), and
Fourth Military Medical University Hospital of Stomatology (Central-C,
n = 31) between 2009 and 2011. The biopsy specimens were ﬁxed in
neutral buffered formalin, embedded in parafﬁn, and stained with
H&E. The baseline OED lesions were classiﬁed as mild, moderate, or
severe by at least two senior pathologists using the same criteria from
the 2005 WHO Classiﬁcation System (Gale et al., 2005). The sample
size was calculated according to results of our previous single center
study (Cao et al., 2009).
All cases involved primary lesions with no prior surgical, LASER,
radiation therapy, or chemotherapy treatments. Information on clinical
variables, lesion site, cigarette smoking, alcohol use, and past medical
history was also collected. Follow-up examination was regularly per-
formed every three months in a double-blind pattern for at least three
years as described previously (Cao et al., 2009). If malignant develop-
ment was observed, an additional examination and re-biopsy wereFig. 1. Participant ﬂow diagram.carried out. Patients who did not require a re-biopsy during the
follow-up examination period due to an obvious disappearance/regres-
sion of the baseline lesion continued to undergo extensive examinations
(Fig. 1). The study was approved by the Institutional Review Boards of
the Peking University Cancer Hospital, and all patients gave written
informed consent. This trial is registered in the U.S. National Institutes
of Health Clinical Trials Protocol Registration System in accordance
with the criteria outlined by the International Committee of Medical
Journal Editors (trial number NCT01695018, available at http://
ClinicalTrials.gov).
2.2. Quantiﬁcation of P16 Methylation Using the 115-bp MethyLight
Genomic DNA from the OED biopsy samples was extracted from the
frozen tissues or parafﬁn blocks (Cao et al., 2009). Genomic DNA sam-
ples (2 μg) were treated with 5 M sodium bisulﬁte for 16 h at 50 °C
without desulfonation as described. The proportion of 115-bp meth-
ylated fragments from the sense-strand of P16 exon-1 copies was
analyzed using the 115-bp MethyLight assay previously established
to quantify the P16 methylation level for clinical diagnosis (Zhou
et al., 2011), however, uracil DNA glycosylase and dUTP were
not added into the reaction mixture. The 115-bp sense-fragment
is completely included within P16 exon-1, the most prevalent
sequence investigated for P16 methylation. Methylation in this re-
gion is not only correlated with inactivation of this gene (Herman
et al., 1995), but also associated with prognosis of epithelial dyspla-
sia (Sun et al., 2004; Cao et al., 2009; Zhou et al., 2011). Brieﬂy, the
115-bp methylated fragment in the sense-strand of P16 exon-1 was
ampliﬁed using forward primer (5′-CgCggtCgtggttagttagt-3′),
reverse primer (5′-tacGctcGacGactaCgaaa-3′), and P16-speciﬁc
probe (6FAM-gttgtttttCgtCgtCggtt-TAMRA). The 25 μl MethyLight
reaction mixture contained 12.5 μl Maxima Probe/ROX qPCR Master
Mix (2×) (#K0233, Thermo Scientiﬁc Fermentas Mix), 0.75 μl of
10 μmol/L of each primer (TaKaRa, Beijing), 0.75 μl of 10 μmol/L
probe (TaKaRa), and 8 ng of template. An ABI7500 fast thermal
cycler was used to perform the PCR reactions using the following
thermal conditions: 37 °C for 10 min→ 95 °C for 30 min→ (95 °C
for 15 s → 62 °C for 1 min) × 45 cycles. The ﬂuorescence signal
was detected at 62 °C. Samples were run in duplicate, and the aver-
age Ct value was calculated. The COL2A1 gene, a CpG island-free gene
whose copy number was not effected by methylation status in the
MethyLight assay, was used as input reference and ampliﬁed with
forward primer (5′-tctaacaattataaactccaaccaccaa-3′), reverse primer
(5′-gggaagatgggatagaagggaatat-3′), and COL2A1-speciﬁc probe (6FAM-
ccttcattctaacccaatacctatcccacctctaaa-BHQ1) (Widschwendter et al.,
2004). Relative copy number (RCN) of methylated-P16 was calculated
according to the formula [2−ΔCt, (ΔCt = Ctmethylated-P16 − CtCOL2A1)].
Genomic DNA samples from the human colon cancer cell line RKO con-
taining completely methylated P16 alleles and P16 unmethylated
MGC803 cell xenografts were used as P16 methylation-positive and
-negative controls for each experiment, respectively (Cao et al., 2009).
These cell lines were tested and authenticated by Beijing Jianlian
Genes Technology Co., Ltd before being used in this study as we
described previously (Liu et al., 2014).
2.3. Determining P16 Methylation State Deﬁnition
In order to steadily detect ﬂuorescence signal for methylated-P16 at
the proportion of 1/64 (1.56%), eachMethyLight reaction (25 μl) should
contain at least 8 ng bisulﬁte-modiﬁed template DNA that would result
in the Ct value for the input reference COL2A1 ≤ 29.3. Using less tem-
plate DNA would lead to false methylation-negative results. Therefore,
when the cutoff value for P16 methylation-positive was set at 1/64,
only DNA samples with an average COL2A1-Ct value ≤ 29.3 were con-
sidered as P16 methylation-informative. All of the frozen samples and
80% of the parafﬁn embedded samples met the P16 methylation-
Table 1
Demographic and clinical characteristics of the patients with oral epithelial dysplasia en-
rolled into the ﬁnal follow-up analysis.
Status of p16methylation n Age (years) Sex
Range Mean ± SD Male (%) Female (%)
Methylation-positive 48 25–78 59.3 ± 10.4⁎ 20 (41.7) 28 (58.3)
Methylation-negative 99 33–77 54.7 ± 11.2 46 (46.5) 53 (53.5)
(Total) 147 25–78 56.2 ± 11.1 66 (44.9) 81 (55.1)
⁎ Methylated group vs. unmethylated group, Student's t-test, P = 0.011.
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is detected in the informative samples, it is deﬁned as P16methylation-
positive; otherwise, it is considered P16methylation-negative.
2.4. P16 Immunohistochemical Staining (IHC)
Mouse monoclonal antibody against human P16 protein (ZM-0205,
ZYMED, USA) and the 2-step plus poly-HRP anti-mouse IgG detection
system (PV-9000, GBI, USA) were used to stain oral mucosal biopsy
slides according to the manufactures' protocol. Slides were then coun-
terstained with hematoxylin.
2.5. Statistical Analysis
Results were displayed by constituent ratios of enumeration or
ranked data. SPSS 13.0 software was used to perform univariate and
multivariate analyses with the Chi Square test and binary logistic
regression analysis. Student's t-test was used to analyze age data. All
P-values were two-sided, and P b 0.05 was considered statistically sig-
niﬁcant. Each biopsy at baseline and follow-up analysis was assigned a
severity score according to its histopathologic diagnosis: 1 for carcino-
ma, 2 for severe grade OED, 3 for moderate grade OED, 4 for mild OED,
5 for hyperplasia, and 6 for normal.
3. Results
3.1. Demographics and Clinical Characteristics of the Patients
Of the baseline mild and moderate OED cases, 152 of 181 cases met
the criteria to appropriately classify the P16methylation state using theTable 2
Comparison of P16methylation-positive rate andmalignant transformation of oral epithelial dy
iate and multivariate analyses.
Item All cases P16
n P16M-positive rate Cancer rate n
Sex Male 66 30.3% 6.1% 20
Female 81 34.6% 21.0%a,d 28
Age (y) b60 93 29.0% 14.0% 27
≥60 54 38.9% 14.8% 21
Cigarette smoking Yes 43 30.2% 7.0% 13
No 104 33.7% 17.3% 35
Alcohol use Yes 26 26.9% 3.8% 7
No 121 33.9% 16.5% 41
Baseline grade Mild 97 32.0% 16.5% 31
Moderate 50 34.0% 10.0% 17
Lesion sites Tongue 71 40.8% 23.9%b,e 29
Others 76 25.5% 5.3% 19
Central A 69 36.2% 10.1% 25
B 62 29.0% 19.4% 18
C 16 31.3% 12.5% 5
Sample storages Frozen 41 31.7% 9.8% 13
Parafﬁn 106 35.7% 16.0% 35
(Total) 147 32.7% 14.3% 48
a,b,cDifferences of cancer rates between two subgroups are statistically signiﬁcant in univariate a
ratio: 3.41 (95% CI: 0.66–17.72), 4.75 (1.31–17.16), 3.64 (1.29–10.27), respectively, after sex, ag
The values are presented in the bold letters when difference between two subgroups is statisti115-bp MethyLight analysis (COL2A1-Ct value ≤ 29.3) and 29 cases
were classiﬁed as non-methylation-informative (Fig. 1). 5 methylation-
negative cases were lost during the follow-up period because of changes
of contact information. Thus, 147 cases with follow-up information
were ultimately enrolled into the ﬁnal cohort analysis giving an
overall compliance of 96.7%. 48 samples were ultimately classiﬁed as
P16 methylation-positive. The average age of patients with P16
methylation-positive OED was signiﬁcantly higher than that of the
P16methylation-negative patients (59.3 years vs 54.7 years, Student's
t-test, P = 0.011; Table 1). Most patients with a positive smoking
(40/43) or drinking history (23/26) were male.
Malignant transformation of OED to OSCCwas observed in 21 of 147
(14.3%) patients during the follow-up (range, 3 to 129months;median,
41 months) (Supplementary ﬁgure). The average baseline age of the
patients that underwent malignant progression was similar to that of
patients that remained stable (56.5 years vs 56.1 year). The overall can-
cer rate was signiﬁcantly higher in females than males (21.0% vs 6.1%,
Chi-square test, P b 0.020; Table 2). Similarly, OED lesions of the tongue
showed signiﬁcantly higher rates of cancer progression than those at
other sites (23.9% vs 5.3%; P b 0.003). Interestingly, the risk of OSCC
development was slightly increased in these patients without smoking
and alcohol use history.
Next, the expression status of P16 in representative OED and OSCC
samples was analyzed using the IHC assay (Fig. 2). Results of IHC analy-
sis showed that P16 protein was located in both the cytoplasm and nu-
cleus of epithelial cells in OED lesions, but only in the cytoplasm of OSCC
cells. Additionally, a greater quantity of P16-positive staining epithelial
cells was observed in the P16 methylation-negative samples than in
the P16methylation-positive samples.
3.2. P16Methylation Is an Early Predictor forMalignant Progression of OED
The rate of progression of OED to OSCC in the 48 P16methylation-
positive patients was consistently higher than that of 99 P16
methylation-negative patients when analyzing different subgroups
including: sex, age, baseline grade, lesion site, center, and specimen
storage medium. Multivariate analysis showed that the risk of malig-
nant transformation for P16 methylation-positive OEDs was signiﬁ-
cantly higher than the negative OEDs after adjustment for age, sex,
smoking, alcohol use, lesion site, and OED grade (adjusted odds
ratio = 4.28, 95% conﬁdence interval [CI]: 1.42–12.87; P = 0.002)splasia between different subgroupswith andwithout P16methylation (P16M) in univar-
M-positive cases P16M-negative cases Odd ratio in univariate analysis
(95% CI)
Cancer cases (%) n Cancer cases (%)
3 (15.0) 46 1 (2.2)
10 (35.7) 53 7 (13.2) 3.65 (1.06–12.82)
8 (29.6) 66 5 (7.6) 5.14 (1.31–20.97)
5 (23.8) 33 3 (9.1)
2 (15.4) 30 1 (3.3)
11 (31.4) 69 7 (10.1) 4.06 (1.26–13.36)
1 (14.3) 19 0
12 (29.3) 80 8 (10.0) 3.72 (1.25–11.29)
11 (35.5) 66 5 (7.6) 6.71 (1.85–25.65)
2 (11.8) 33 3 (9.1)
11 (37.9) 42 6 (14.3) 3.67 (1.03–13.52)
2 (10.5) 57 2 (3.5)
6 (24.0) 44 1 (2.3) 13.58 (1.43–320.9)
6 (33.3) 44 6 (13.6)
1 (20.0) 11 1 (9.1)
4 (30.8) 28 0 Undeﬁned
9 (25.7) 71 8 (11.3)
13 (27.1) 99 8 (8.1) 4.22 (1.47–12.35)c,f
nalysis (Fisher's exact test, P= 0.020, 0.003, 0.002, two sides, respective. d,e,fAdjusted odds
e, smoking, alcohol use, lesion site, and OED grade were adjusted in multivariate analysis.
cally signiﬁcant.
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patients with P16 methylation-positive OED was also signiﬁcantly dif-
ferent from those with the P16 methylation-negative OED (log-rank
test, P = 0.002; Fig. 3).
The area under the receiver operating characteristic curve (ROC) is
0.693 (95% CI: 0.56–0.83; P = 0.005; Fig. 4). Using a relative copy
number cutoff point of 8.21 × 10−5, the sensitivity and speciﬁcity
for early prediction of OED malignant transformation using the P16
methylation-positive classiﬁcation as a biomarker were 62% (13/21)
and 76% (96/126), respectively.
4. Discussion
Early prediction of the malignant potential of OED is crucial for clin-
ical management of patients with the disease. Sincemethylation chang-
es occurring in only a small number of cells can now be sensitively
detected in tissues containingmultiple cell types, alterations in promot-
er methylation may ultimately offer optimal biomarkers for predicting
the malignant potential of precancerous lesions (Deng et al., 2010). In
this multicentre prospective study, we observed that P16methylation
was a signiﬁcant, independent predictor of malignant progression ofFig. 2. P16 immunohistochemical staining images. Photos of the baseline oral epithelial dyspla
weak, and negative P16 staining in the cytoplasm and nucleus of squamous epithelial cells, resp
cancer cells, respectively; A, B, D: P16methylation-negative; C and E: P16methylation-positive
containing only silenced P16 alleles by methylation; white black bar: 60 μm.OED with a sensitivity and speciﬁcity of 62% and 76%, respectively.
This is consistent with the results of two small single-center studies
in China and Britain (Hall et al., 2008; Cao et al., 2009). Collectively,
these studies indicate that P16 methylation signiﬁcantly correlates
with malignant progression of OED and could be used as a useful bio-
marker for personalizing the management of patients with this disease.
In regularmethylation analysis usingMSP andother PCR-basedmeth-
ylation assays, a tested sample is generally considered methylation-
informative after a PCR product for the methylated- or unmethylated-
fragment of CpG islands is obtained. However, we found that the quantity
of input DNA was a crucial factor in accurately determining the level
of P16 methylation in parafﬁn embedded samples when using the
MethyLight assay. We found that at least 8 ng of bisulﬁte-modiﬁed,
single-stranded DNA in the 25 μl MethyLight reaction mixture was
required to generate Ct values for the input reference COL2A1 b 29.3,
which allowed the proportion of 1/64 of methylated-P16 to be consis-
tently detected. Therefore, in order to ensure accurate results, only sam-
ples with the reference Ct value b 29.3 were considered as P16
methylation-informative. The signiﬁcance of this ﬁnding is that sufﬁ-
cient amounts of input DNA are required for all accurate quantitative
methylation analyses.sia (OED) and oral squamous cell carcinoma (OSCC). A, B, and C: OED lesions with strong,
ectively; D and E: OSCCwith extensively and focally moderate staining in the cytoplasm of
; F: P16-negative control, an xenograft originated from human colon cancer cell line RKO
Fig. 3.Malignant transformation Kaplan–Meier curves for patients with P16methylation-
positive and negative oral epithelial dysplasia. The log-rank test, P = 0.002.
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at least 1.56% of input cells may be malignantly transformed. However,
increasing the amount of input DNA could increase the number of
samples detected as methylation-positive, especially for parafﬁn
samples containing b1.56% P16-methylated cells. Therefore, because
it is unknown if OEDs containing b1.56% methylated-P16 have a
higher risk of malignant progression when compared to OEDs with no
methylated-P16, we could not exclude that a P16 methylation-
positive classiﬁcation for this part of samples could be clinically false
methylation-positive.
Although the average age of the P16 methylation-positive patients
was higher than that of P16methylation-negative patients, multivariate
analysis revealed that P16 methylation is still signiﬁcantly associated
with malignant transformation of OEDs after adjusting for age. This
indicates that P16methylation is an independent predictor of this dis-
ease prognosis.
It is well known that 5-methylcytosine in DNA may further be oxi-
dized into hydroxymethylation, which cannot be distinguished fromFig. 4. ROC curve of prediction of malignant progression of oral epithelial dysplasia by dif-
ferent P16methylation levels. The area under the curve is 0.693 (95% CI: 0.56-0.83, P =
0.005). Green dot, cutoff point of relative copy number of methylated-P16, 8.21 × 10−5.true methylation using regular methylation assays. We have recently
reported hydroxymethylation of P16 CpG islands in cancer cells Qin
et al., 2014 and observed that P16-speciﬁc hydroxymethylation can
reactivate transcription of methylated-P16 alleles (unpublished data;
Deng D et al.). It is necessary to further clarify if combined analysis of
both true P16 methylation and hydroxymethylation (or other deriva-
tives) might improve clinical performance of the methylation marker.
The causality of P16methylation with OSCC development also requires
further study.
An Italian group has reported that there is no eminent beneﬁt to
surgical intervention of OED in preventing recurrences and malignant
development (Arduino et al., 2009). In our previous study, we described
that the risk of cancer progression inOEDpatientswith surgical excision
was even slightly higher than thosewithout surgical excision, especially
in patients with P16methylation-positive OED (Cao et al., 2009). There-
fore, surgical interventionmight need to be avoided in themanagement
formild andmoderate OEDpatients. OnlyOEDpatientswithout surgical
excision were included in the present multicentre prospective study.
Ho M et al. have reported that non-smoking status is a signiﬁcant
predictor for malignant transformation of OED patients in the UK (Ho
et al., 2012). In the present study, OED patients with a negative smoking
or alcohol use history showed a higher OSCC progression rate than
patients with a positive history, although the difference in cancer risk
was not signiﬁcant.
In conclusion, P16methylation could be used as an additional tool in
helping to predict themalignant potential of OED. Combinedwith other
diagnostic and prognostic factors, P16methylation could help to shape
an individualized treatment plan for OED patients. While it is still
unknown if these results can be generalized across all populations,
detection of P16methylation should be carried out at least for Chinese
OED patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.03.015.
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